Ultrasound check for intramuscular bleeding after needle EMG in people taking DOACs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational protocol enrolling people who are taking DOACs and who undergo needle electromyography (EMG). About 30 minutes after the EMG, an ultrasound exam of the muscles where needles were inserted will be performed to look for possible intramuscular hematomas. Subjects on any additional antithrombotic medications are excluded to isolate the effect of DOAC therapy. The goal is to determine whether routine needle EMG poses a bleeding risk in this patient group without altering their anticoagulant regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures
* Willing and able to comply with all protocol procedures
* subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.
* no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.

Exclusion Criteria:

* Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject
* other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.

Where it's running

• University Hospital Brno
  Brno, Czech Republic, Czechia Recruiting
• University hospital Brno
  Brno, Czech Republic, Czechia Recruiting

Study contacts

• Study coordinator: Adam Betík, MD
• Email: betik.adam@fnbrno.cz
• Phone: +420532232503

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultrasound-guided ulnar nerve PCR test to diagnose and monitor leprosy

  This test uses an ultrasound-guided needle sample from the ulnar nerve combined with PCR to see if it can detect Mycobacterium leprae and help diagnose or monitor people with suspected or confirmed leprosy.

  Recruiting University of Brasilia · Brasília, Federal District · NCT07515989

• Registering medical data and care outcomes for ALS, SMA, and other motor disorders

  This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.

  Recruiting Ambulanzpartner Soziotechnologie APST GmbH · Berlin, State of Berlin · NCT07900672

• How chronic pain changes over time in kids with Duchenne Muscular Dystrophy

  This study is following children and teens with Duchenne Muscular Dystrophy for 6 months to see how their chronic pain changes and how it affects daily life.

  Recruiting Antalya Training and Research Hospital · Antalya, Antalya · NCT07892196

• Able Kids device: safer gait aid for kids with neurologic gait problems

  This study tests whether the ABLE Kids wearable exoskeleton can be safely used during a 10-session gait training program for children with neurological gait disorders or muscle weakness.

  Recruiting ABLE Human Motion S.L. · Girona, Girona · NCT07745712

• 3D-Printed Hand Orthosis for ADL in Chronic Hand Conditions

  This study tests whether a 3D-printed hand orthosis works as well as a traditional plaster-cast orthosis for improving daily activities in adults with chronic hand conditions.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT07633821

• Zeleciment Rostudirsen (DYNE-251) for Duchenne Muscular Dystrophy in Ambulatory Boys

  This trial tests whether intravenous Zeleciment Rostudirsen (DYNE-251) given every 4 weeks is safe and helps improve function in ambulatory boys with Duchenne muscular dystrophy who have a specific dystrophin gene mutation.

  Recruiting Phase 3 Dyne Therapeutics · Hillsborough, North Carolina · NCT07608432

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.